Erkan Yuca

1.0k total citations
21 papers, 492 citations indexed

About

Erkan Yuca is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erkan Yuca has authored 21 papers receiving a total of 492 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erkan Yuca's work include HER2/EGFR in Cancer Research (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Advanced Breast Cancer Therapies (4 papers). Erkan Yuca is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Advanced Breast Cancer Therapies (4 papers). Erkan Yuca collaborates with scholars based in United States, Japan and Egypt. Erkan Yuca's co-authors include Bülent Özpolat, Gabriel Lopez‐Berestein, Anil K. Sood, İbrahim Tekedereli, Kurt W. Evans, Funda Meric‐Bernstam, Argun Akçakanat, Ming Zhao, Uǧur Akar and S. Neslihan Alpay and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Scientific Reports.

In The Last Decade

Erkan Yuca

20 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erkan Yuca United States 11 323 188 122 100 51 21 492
Florian Bellutti Austria 7 281 0.9× 196 1.0× 163 1.3× 99 1.0× 86 1.7× 13 538
Samar Alanazi United States 8 347 1.1× 271 1.4× 102 0.8× 66 0.7× 48 0.9× 13 575
Carlos R. Gil Del Alcazar United States 7 247 0.8× 205 1.1× 80 0.7× 109 1.1× 91 1.8× 9 440
Ján Gurský Czechia 13 271 0.8× 137 0.7× 54 0.4× 99 1.0× 66 1.3× 22 466
Adrian P. Rybak Canada 12 450 1.4× 265 1.4× 174 1.4× 157 1.6× 22 0.4× 17 644
Sei Sai South Korea 12 203 0.6× 137 0.7× 159 1.3× 128 1.3× 70 1.4× 25 492
Grace R. Anderson United States 11 573 1.8× 190 1.0× 63 0.5× 210 2.1× 50 1.0× 13 763
Justin Cidado United States 12 394 1.2× 187 1.0× 67 0.5× 83 0.8× 46 0.9× 36 561
Yoshinari Shinsato Japan 14 284 0.9× 164 0.9× 72 0.6× 129 1.3× 75 1.5× 20 523

Countries citing papers authored by Erkan Yuca

Since Specialization
Citations

This map shows the geographic impact of Erkan Yuca's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erkan Yuca with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erkan Yuca more than expected).

Fields of papers citing papers by Erkan Yuca

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erkan Yuca. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erkan Yuca. The network helps show where Erkan Yuca may publish in the future.

Co-authorship network of co-authors of Erkan Yuca

This figure shows the co-authorship network connecting the top 25 collaborators of Erkan Yuca. A scholar is included among the top collaborators of Erkan Yuca based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erkan Yuca. Erkan Yuca is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meric‐Bernstam, Funda, Erkan Yuca, Kurt W. Evans, et al.. (2024). Antitumor Activity and Biomarker Analysis for TROP2 Antibody–Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clinical Cancer Research. 31(3). 573–587. 7 indexed citations
2.
Saridogan, Turçin, Argun Akçakanat, Ming Zhao, et al.. (2023). Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Scientific Reports. 13(1). 20223–20223. 12 indexed citations
3.
Meric‐Bernstam, Funda, Erkan Yuca, Kurt W. Evans, et al.. (2023). 33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models. ESMO Open. 8(1). 101257–101257. 1 indexed citations
4.
Erdoğan, Mümin Alper, et al.. (2022). SCN5A promotes the growth and lung metastasis of triple-negative breast cancer through EF2-kinase signaling. Life Sciences. 313. 121282–121282. 3 indexed citations
5.
Yuca, Erkan, Kurt W. Evans, Argun Akçakanat, et al.. (2022). Abstract 1768: Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models. Cancer Research. 82(12_Supplement). 1768–1768. 1 indexed citations
6.
Li, Dali, Kurt W. Evans, Maria Gabriela Raso, et al.. (2021). Abstract P058: Anti-tumor activity of ATR inhibitor BAY 1895344 in patient-derived xenograft (PDX) models with DNA damage response (DDR) pathway alterations. Molecular Cancer Therapeutics. 20(12_Supplement). P058–P058.
7.
Zhao, Ming, Erkan Yuca, Kurt W. Evans, et al.. (2021). First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Research. 23(1). 29–29. 48 indexed citations
8.
Zhao, Ming, Kurt W. Evans, Erkan Yuca, et al.. (2021). Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clinical Cancer Research. 27(6). 1681–1694. 44 indexed citations
9.
Erdoğan, Mümin Alper, Ahmed A. Ashour, Erkan Yuca, Kıvanç Görgülü, & Bülent Özpolat. (2021). Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer. Cellular Signalling. 81. 109938–109938. 16 indexed citations
10.
Evans, Kurt W., Argun Akçakanat, Erkan Yuca, et al.. (2019). TAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget. 10(49). 5011–5019. 4 indexed citations
11.
Zhao, Ming, et al.. (2018). Abstract 5802: Efficacy of PI3Kβ inhibitor AZD8186 in PTEN-deficient triple-negative breast cancer. Cancer Research. 78(13_Supplement). 5802–5802. 2 indexed citations
12.
Evans, Kurt W., Erkan Yuca, Argun Akçakanat, et al.. (2017). A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clinical Cancer Research. 23(21). 6468–6477. 48 indexed citations
13.
Yuca, Erkan, Ming Zhao, Kurt W. Evans, et al.. (2017). Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Research. 19(1). 93–93. 46 indexed citations
14.
Meric‐Bernstam, Funda, Kurt W. Evans, Xiaofeng Zheng, et al.. (2017). Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy. Cancer Research. 77(13_Supplement). 4970–4970. 1 indexed citations
15.
Zhao, Ming, Kurt W. Evans, Erkan Yuca, et al.. (2017). Abstract 4038: Exploring optimal targeted combination therapies with neratinib for HER2+ breast cancer. Cancer Research. 77(13_Supplement). 4038–4038. 1 indexed citations
16.
Evans, Kurt W., Ming Zhao, Erkan Yuca, et al.. (2016). Abstract 3075: Nuclear export inhibitor selinexor (KPT-330) demonstrates anti-tumor efficacy alone and in combination with chemotherapy in multiple breast cancer models. Cancer Research. 76(14_Supplement). 3075–3075. 1 indexed citations
17.
Jin, Yang, Ling Wang, Su Qu, et al.. (2015). STAMP 2 increases oxidative stress and is critical for prostate cancer. EMBO Molecular Medicine. 7(3). 315–331. 49 indexed citations
18.
19.
Jin, Yang, Su Qu, Martina Tesikova, et al.. (2013). Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proceedings of the National Academy of Sciences. 110(28). E2572–81. 53 indexed citations
20.
Shao, Longjiang, İbrahim Tekedereli, Jianghua Wang, et al.. (2012). Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors. Clinical Cancer Research. 18(24). 6648–6657. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florian Bellutti Breakdown of academic impact, for papers by Samar Alanazi Breakdown of academic impact, for papers by Carlos R. Gil Del Alcazar Breakdown of academic impact, for papers by Ján Gurský Breakdown of academic impact, for papers by Adrian P. Rybak Breakdown of academic impact, for papers by Sei Sai Breakdown of academic impact, for papers by Grace R. Anderson Breakdown of academic impact, for papers by Justin Cidado Breakdown of academic impact, for papers by Yoshinari Shinsato
Rankless by CCL
2026